La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Beam Therapeutics Gestion
Gestion contrôle des critères 4/4
Beam Therapeutics' CEO is John Evans, appointed in Apr 2017, has a tenure of 7.42 years. total yearly compensation is $6.28M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 1.18% of the company’s shares, worth $23.45M. The average tenure of the management team and the board of directors is 5 years and 4.3 years respectively.
Informations clés
John Evans
Directeur général
US$6.3m
Rémunération totale
| Pourcentage du salaire du PDG | 10.9% |
| Durée du mandat du directeur général | 7.4yrs |
| Propriété du PDG | 1.2% |
| Durée moyenne d'occupation des postes de direction | 5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.3yrs |
Mises à jour récentes de la gestion
Recent updates
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$143m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$285m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$134m |
| Mar 31 2019 | n/a | n/a | -US$124m |
| Dec 31 2018 | US$4m | US$441k | -US$117m |
Rémunération vs marché: John's total compensation ($USD6.28M) is about average for companies of similar size in the US market ($USD5.54M).
Rémunération et revenus: John's compensation has been consistent with company performance over the past year.
PDG
John Evans (46 yo)
7.4yrs
Titularisation
US$6,280,099
Compensation
Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2020. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 7.4yrs | US$6.28m | 1.18% $ 23.5m | |
| President | 4.7yrs | US$2.79m | 0.13% $ 2.7m | |
| Senior VP | 5.4yrs | US$2.28m | 0.054% $ 1.1m | |
| Chief Medical Officer | 3.5yrs | US$2.55m | 0.0017% $ 34.3k | |
| Co-Founder | no data | pas de données | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| Co-Founder | no data | pas de données | pas de données | |
| Senior VP of Finance & Treasurer | no data | pas de données | 0.0063% $ 124.6k | |
| Chief Technology Officer | no data | pas de données | pas de données | |
| Chief Scientific Officer | 1.5yrs | pas de données | pas de données | |
| Chief Human Resources Officer | 7.1yrs | pas de données | pas de données | |
| Chief Manufacturing Officer | no data | pas de données | pas de données |
5.0yrs
Durée moyenne de l'emploi
56.5yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de BEAM est chevronnée et expérimentée (5 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | no data | US$6.28m | 1.18% $ 23.5m | |
| Independent Director | 2.8yrs | US$435.22k | 0% $ 0 | |
| Independent Lead Director | 6.3yrs | US$465.22k | 0.022% $ 426.0k | |
| Independent Director | 4.9yrs | US$450.22k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$447.72k | 0% $ 0 | |
| Independent Director | less than a year | US$772.68k | pas de données | |
| Independent Director | 5.8yrs | US$442.72k | 0% $ 0 |
4.3yrs
Durée moyenne de l'emploi
57yo
Âge moyen
Conseil d'administration expérimenté: BEAM's board of directors are considered experienced (4.3 years average tenure).